Trial Profile

A Multicenter, Randomized, Placebo-Controlled, Multiple-Ascending-Dose Investigation of the Oral Anti-Inflammatory Agent BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Mar 2025 According to an Adiso Therapeutics media release, ADS051 data generated from two Phase 1 studies(Single Ascending Dose Study and Multiple Ascending Dose Study) has been submitted to the United States (U.S.) Food and Drug Administration (FDA) within an end-of-Phase 1 meeting.
06 Mar 2025 According to an Adiso Therapeutics media release, results from this study has been published in the American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG).
06 Mar 2025 Results published in Adiso Therapeutics, Inc the Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com